AMGN Still Below Our Buy Under, Trading Target Raised

Amgen broke from a bullish consolidation channel on high volume and a breakaway gap

   
AMGN Still Below Our Buy Under, Trading Target Raised

Amgen (NASDAQ:AMGN) — This biotech company has been a leader in the development of genetically based research and treatment for cancer, anemia, rheumatoid arthritis and a host of other major illnesses. It markets five of the world’s best-selling biotech drugs.

AMGN has a dividend yield of 2.2% and is recognized as a company with a very high cash position, giving it the flexibility for acquisition and further drug developments. On Tuesday, S&P raised their 2013 earnings per share (EPS) estimate $0.03 to $7.21, and their fundamental target $4 to $104.

This week, the stock broke from a bullish consolidation channel on high volume and a breakaway gap. Support is at a three-point line at $82, which intersects with the 200-day moving average. Our trading target for AMGN is raised to $110, but it is also recommended as a long-term investment. The buy under price is $90.

02 27 13 amgn 300x202 AMGN Still Below Our Buy Under, Trading Target Raised
Click to Enlarge

chart key 300x84 AMGN Still Below Our Buy Under, Trading Target Raised


Article printed from InvestorPlace Media, http://investorplace.com/2013/02/trade-of-the-day-amgen-nasdaq-amgn-6/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.